Yan V. Wang

Atezolizumab, an Anti–Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study

David F. McDermott, Jeffrey A. Sosman, Mario Sznol et al. · Journal of Clinical Oncology · 2016 · 558 citations

Medicine, Oncology, Pharmacology +17

Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer

Carol Aghajanian, Barbara A. Goff, Lawrence R. Nycum et al. · Gynecologic Oncology · 2015 · 315 citations · Full text

Medicine, Gynecology, Oncology +17

The Xolair Pregnancy Registry (EXPECT): The safety of omalizumab use during pregnancy

Jennifer A. Namazy, Michael D. Cabana, Angela E. Scheuerle et al. · Journal of Allergy and Clinical Immunology · 2014 · 246 citations

Medicine, Gynecology, Obstetrics +11

A phase Ib/II study of the anti-CD47 antibody magrolimab with cetuximab in solid tumor and colorectal cancer patients.

George A. Fisher, Nehal J. Lakhani, Cathy Eng et al. · Journal of Clinical Oncology · 2020 · 53 citations

Medicine, Oncology, Pharmacology +15

A phase Ib study of the anti-CD47 antibody magrolimab with the PD-L1 inhibitor avelumab (A) in solid tumor (ST) and ovarian cancer (OC) patients.

Nehal J. Lakhani, Amita Patnaik, John B. Liao et al. · Journal of Clinical Oncology · 2020 · 37 citations

Medicine, Oncology, Pharmacology +17